Literature DB >> 29657876

Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review.

Akanksha Joshi1, Chokkalingam Siva1.   

Abstract

Calcium pyrophosphate deposition (CPPD) disease, also known as pseudogout, is one of the most common forms of inflammatory arthritis. A variety of comorbidities and metabolic conditions have been recognized to predispose to CPPD. We describe here a patient with chronic CPP arthritis due to hypomagnesemia, which is one of the metabolic etiologies associated with CPPD, especially in younger patients. We also performed a literature search and reviewed all reported cases of CPPD disease associated with hypomagnesemia. All cases of hypomagnesemia and its etiologies leading to CPP arthropathy identified in the literature by this systematic search are summarized in this paper.

Entities:  

Keywords:  CPPD; Magnesium; calcium pyrophosphate deposition disease; chondrocalcinosis; hypomagnesemia; pseudogout

Year:  2017        PMID: 29657876      PMCID: PMC5895153          DOI: 10.5152/eurjrheum.2017.16116

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  46 in total

1.  Bartter's syndrome presenting as pseudomyocardial infarction and pseudogout.

Authors:  A D Waitman; M Koffler; N Kaplinsky
Journal:  Isr J Med Sci       Date:  1992-12

2.  Pseudoneuropathic CPPD arthropathy: magnesium matters.

Authors:  B R Whelan; F O'Shea; G McCarthy
Journal:  Rheumatology (Oxford)       Date:  2008-02-12       Impact factor: 7.580

3.  Calcium pyrophosphate dihydrate crystal deposition disease: nomenclature and diagnostic criteria.

Authors:  D J McCarty
Journal:  Ann Intern Med       Date:  1977-08       Impact factor: 25.391

4.  Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.

Authors:  Axel Finckh; Geraldine M Mc Carthy; Anne Madigan; Daniel Van Linthoudt; Marcel Weber; David Neto; Georges Rappoport; Sandra Blumhardt; Diego Kyburz; Pierre-Andre Guerne
Journal:  Arthritis Res Ther       Date:  2014-10-15       Impact factor: 5.156

5.  Chondrocalcinosis associated with Bartter's syndrome and hypomagnesemia.

Authors:  S Muñoz-Fernández; L Pantoja; E Martin Mola; E de Miguel; J Gijón Baños
Journal:  J Rheumatol       Date:  1994-09       Impact factor: 4.666

6.  "Pseudoseptic" pseudogout associated with hypomagnesemia in liver transplant patients.

Authors:  F Perez-Ruiz; M Testillano; M A Gastaca; A M Herrero-Beites
Journal:  Transplantation       Date:  2001-03-15       Impact factor: 4.939

7.  [Chondrocalcinosis and hypomagnesemia: clinical and radiological progression].

Authors:  José González Domínguez; Alejandro Escudero Contreras; Verónica Pérez Guijo; Francisco Ginés Martínez Sánchez; Miguel Ángel Caracuel Ruiz; Eduardo Collantes Estévez
Journal:  Reumatol Clin       Date:  2008-10-28

8.  European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.

Authors:  W Zhang; M Doherty; T Bardin; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; E Pascual
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

9.  [Articular chondrocalcinosis and hypomagnesemia of renal origin. Apropos of 2 cases].

Authors:  M A Mayoux-Benhamou; D Clerc; D Ganeval; N Pertuisset; P Massias
Journal:  Rev Rhum Mal Osteoartic       Date:  1985-10

10.  Familial hypokalemia/hypomagnesemia and chondrocalcinosis.

Authors:  T J Smilde; J F Haverman; P Schipper; A R Hermus; F J van Liebergen; J L Jansen; P W Kloppenborg; M I Koolen
Journal:  J Rheumatol       Date:  1994-08       Impact factor: 4.666

View more
  3 in total

Review 1.  [Chondrocalcinosis: idiopathic or manifestation of rare metabolic diseases?]

Authors:  J Knitza; A Kleyer; G Schett; B Manger
Journal:  Orthopade       Date:  2019-11       Impact factor: 1.087

2.  Histone Deacetylase Inhibitors Downregulate Calcium Pyrophosphate Crystal Formation in Human Articular Chondrocytes.

Authors:  Chi-Ching Chang; Kun-Lin Lee; Tze-Sian Chan; Chia-Chen Chung; Yu-Chih Liang
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

Review 3.  The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.

Authors:  Alberto Altomare; Addolorata Corrado; Nicola Maruotti; Daniela Cici; Francesco Paolo Cantatore
Journal:  Mol Biol Rep       Date:  2021-06-01       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.